Top Gene Interactions
- Metabolism: Melphalan is not actively metabolised, it spontaneously degrades to mono and dihydroxy products. Route of Elimination: The 24-hour urinary excretion of parent drug in these patients was 10% Њ± 4.5%, suggesting that renal clearance is not a major route of elimination of parent drug. Half Life: 1.5 (±0.83) hours
- Uses/Sources: For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.
- Health Effects: The principal toxic effect is bone marrow suppression.
- Symptoms: Vomiting, ulceration of the mouth, diarrhea, and hemorrhage of the gastrointestinal tract.
- Route of Exposure: Incomplete, variable, 25-89% post oral dose
- Carcinogenicity: 1, carcinogenic to humans. (L135)
- Toxicity: LD<sub>50</sub>=11.2 mg/kg (orally in rat)
Mechanism of Action
|Target Name||Mechanism of Action||References|